dc.contributor.author | Kirsebom, Bjørn-Eivind | |
dc.contributor.author | Nordengen, Kaja | |
dc.contributor.author | Selnes, Per | |
dc.contributor.author | Waterloo, Knut | |
dc.contributor.author | Torsetnes, Silje Bøen | |
dc.contributor.author | Gísladóttir, Berglind | |
dc.contributor.author | Brix, Britta | |
dc.contributor.author | Vanmechelen, Eugeen | |
dc.contributor.author | Bråthen, Geir | |
dc.contributor.author | Hessen, Erik | |
dc.contributor.author | Aarsland, Dag | |
dc.contributor.author | Fladby, Tormod | |
dc.date.accessioned | 2019-04-26T09:23:55Z | |
dc.date.available | 2019-04-26T09:23:55Z | |
dc.date.issued | 2018-11-10 | |
dc.description.abstract | <i>Introduction</i>: The cerebrospinal fluid neurogranin (Ng)/β-site amyloid precursor protein-cleaving
enzyme 1 (BACE1) ratio may reflect synaptic affection resulting from reduced beta-amyloid (Aβ)
clearance. We hypothesize that increased Ng/BACE1 ratio predicts the earliest cognitive decline in
Alzheimer’s disease.<p>
<p><i>Methods</i>: We compared Ng/BACE1 levels between cases with subjective cognitive decline (n = 18)
and mild cognitive impairment (n 5 20) both with amyloid plaques and healthy controls (<i>APOE-ε</i>4+,
n 5 16; <i>APOE-ε</i>4-, n 5 20). We performed regression analyses between cerebrospinal fluid levels,
baseline hippocampal and amygdala volumes, and pertinent cognitive measures (memory, attention,
Mini Mental State Examination [MMSE]) at baseline and after 2 years.<p>
<p><i>Results</i>: Ng/BACE1 levels were elevated in both subjective cognitive decline and mild cognitive
impairment compared to healthy controls. Higher Ng/BACE1 ratio was associated with lower hippocampal and amygdala volumes; lower baseline memory functions, attention, and MMSE; and significant decline in MMSE and memory function at 2-year follow-up.<p>
<p><i>Discussion</i>: High Ng/BACE1 ratio predicts cognitive decline also in preclinical cases with amyloid
plaques.<p> | en_US |
dc.description.sponsorship | Norwegian Research Council
NASATS (Dementia Disease Initiation)
JPND
Helse Sør-Øst
Helse Nord
National Institute for Health Research (NIHR)
Biomedical Research Center at South London
Maudsley NHS Foundation Trust
King’s College London | en_US |
dc.description | Source at <a href=https://doi.org/10.1016/j.trci.2018.10.003>https://doi.org/10.1016/j.trci.2018.10.003. </a> | en_US |
dc.identifier.citation | Kirsebom, B-E., Nordengen, K., Selnes, P., Waterloo, K., Torsetnes, S.B, Gísladóttir, B. ... Fladby, T. (2018). Cerebrospinal fluid neurogranin/β-site APP-cleaving enzyme 1 predicts cognitive decline in preclinical Alzheimer's disease. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i>, 4, 617-627. https://doi.org/10.1016/j.trci.2018.10.003 | en_US |
dc.identifier.cristinID | FRIDAID 1642467 | |
dc.identifier.doi | 10.1016/j.trci.2018.10.003 | |
dc.identifier.issn | 2352-8737 | |
dc.identifier.uri | https://hdl.handle.net/10037/15232 | |
dc.language.iso | eng | en_US |
dc.publisher | Elsevier | en_US |
dc.relation.ispartof | Kirsebom, B-E. (2019). Dementia Disease Initiation: Identifying subjective cognitive decline (SCD) due to Alzheimer’s disease. (Doctoral thesis). <a href=https://hdl.handle.net/10037/15234>https://hdl.handle.net/10037/15234. </a> | |
dc.relation.journal | Alzheimer's and Dementia: Translational Research and Clinical Interventions | |
dc.relation.projectID | info:eu-repo/grantAgreement/NRC/?/?/Norway/?// | en_US |
dc.rights.accessRights | openAccess | en_US |
dc.subject | Alzheimer’s disease | en_US |
dc.subject | MCI (mild cognitive impairment) | en_US |
dc.subject | SCD (subjective cognitive decline) | en_US |
dc.subject | MRI | en_US |
dc.subject | Memory | en_US |
dc.subject | Cognition | en_US |
dc.subject | Synaptic loss | en_US |
dc.subject | Cerebrospinal fluid (CSF) | en_US |
dc.subject | CSF neurogranin | en_US |
dc.subject | CSF BACE1 | en_US |
dc.subject | VDP::Social science: 200::Psychology: 260 | en_US |
dc.subject | VDP::Samfunnsvitenskap: 200::Psykologi: 260 | en_US |
dc.title | Cerebrospinal fluid neurogranin/β-site APP-cleaving enzyme 1 predicts cognitive decline in preclinical Alzheimer's disease | en_US |
dc.type | Journal article | en_US |
dc.type | Tidsskriftartikkel | en_US |
dc.type | Peer reviewed | en_US |